Renovaro Biosciences (RENB) 10-K 27 Feb 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2022	Feb. 27, 2023	Dec. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	000-54478
Entity Registrant Name	ENOCHIAN BIOSCIENCES INC.
Entity Central Index Key	0001527728
Entity Tax Identification Number	45-2559340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1927 Paseo Rancho Castillo
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90032
City Area Code	(305)
Local Phone Number	918-1980
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ENOB
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 242,848,672
Entity Common Stock, Shares Outstanding		55,705,521
ICFR Auditor Attestation Flag	false
Auditor Name	Sadler, Gibb & Associates, LLC
Auditor Location	Draper, UT
Auditor Firm ID	3627

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Jun. 30, 2021
CURRENT ASSETS:
Cash	$ 9,172,142	$ 20,664,410
Prepaids and other assets	392,996	234,583
Total Current Assets	9,565,138	20,898,993
Property and equipment, net	586,536	719,364
OTHER ASSETS
Definite life intangible assets, net	44,268	65,906
Indefinite life intangible assets, net	61,571,000	154,824,000
Goodwill	11,640,000	11,640,000
Deposits and other assets	68,635	20,984
Operating lease rights-of-use assets	1,157,086	1,435,978
Total Other Assets	74,480,989	167,986,868
TOTAL ASSETS	84,632,663	189,605,225
CURRENT LIABILITIES:
Accounts payable – trade	1,401,867	320,559
Accrued expenses	1,031,462	1,182,323
Other current liabilities	220,685	90,602
Contingent consideration liability	2,343,318
Convertible notes payable	1,200,000
Current portion of operating lease liabilities	253,636	292,409
Total Current Liabilities	6,450,968	1,885,893
NON-CURRENT LIABILITIES:
Contingent consideration liability		6,037,945
Convertible notes payable		1,200,000
Notes payable, net	4,577,148	4,579,114
Operating lease liabilities, net of current portion	985,699	1,239,334
Total Non-Current Liabilities	5,562,847	13,056,393
Total Liabilities	12,013,815	14,942,286
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 53,007,082 shares issued and outstanding at June 30, 2022; 52,219,661 shares issued and outstanding at June 30, 2021	5,302	5,222
Additional paid-in capital	276,989,179	265,580,356
Accumulated deficit	(204,345,197)	(90,911,805)
Accumulated other comprehensive (loss)	(30,436)	(10,834)
Total Stockholders’ Equity	72,618,848	174,662,939
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 84,632,663	$ 189,605,225

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	53,007,082	52,219,661
Common stock, shares outstanding	53,007,082	52,219,661

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Expenses
General and administrative	$ 14,329,801	$ 7,557,990
Research and development	8,372,800	15,720,262
Indefinite life intangible assets impairment charge	93,253,000
Depreciation and amortization	123,590	123,535
Total Operating Expenses	116,079,191	23,401,787
LOSS FROM OPERATIONS	(116,079,191)	(23,401,787)
Other Income (Expenses)
Change in fair value of contingent consideration	2,896,627	(3,048,033)
Interest expense	(372,844)	(379,608)
Gain (loss) on currency transactions	9	(32,634)
Interest and other income	122,041	13,179
Total Other Income (Expenses)	2,645,833	(3,447,096)
Loss Before Income Taxes	(113,433,358)	(26,848,883)
Income Tax (Expense) Benefit	(34)	125,276
NET LOSS	$ (113,433,392)	$ (26,723,607)
BASIC AND DILUTED NET LOSS PER COMMON SHARE	$ (2.16)	$ (0.57)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED	52,528,024	47,167,262

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net Loss	$ (113,433,392)	$ (26,723,607)
Other Comprehensive Income (Loss)
Foreign currency translation, net of taxes	(19,602)	30,582
Other Comprehensive Loss	$ (113,452,994)	$ (26,693,025)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Jun. 30, 2020	$ 4,650	$ 230,497,225	$ (64,188,198)	$ (41,416)	$ 166,272,261
Ending Balance, Shares at Jun. 30, 2020	46,497,409
Issuance of commitment shares related to LPC purchase agreement	$ 14	(14)
Issuance of commitment shares related to LPC purchase agreement,shares	139,567
Stock issued pursuant to warrants exercised	$ 6	82,050			82,056
Stock issued pursuant to warrants exercised, Shares	63,122
Contingent shares issued pursuant to acquisition agreement	$ 6	192,516			192,522
Contingent Share issued pursuant to Acquisition Agreement, Shares	63,122
Shares issued pursuant to 2021 private placement	$ 128	5,000,672			5,000,800
Shares issued pursuant to 2021 private placement,shares	1,275,719
Shares issued in lieu of interest on $5 million notes payable extension	$ 7	298,171			298,178
Shares issued in lieu of interest on $5 million notes payable extension,shares	74,054
Shares issued pursuant to LPC purchase agreement	$ 20	1,221,330			1,221,350
Shares issued pursuant to LPC purchase agreement,shares	200,000
Shares issued pursuant to direct offering, net of issuance costs	$ 387	26,843,612			26,843,999
Shares issued pursuant to direct offering, net of issuance costs,shares	3,866,668
Shares issued for fully vested RSUs
Shares issued for fully vested RSUs,shares	5,000
Restricted shares converted to shares for services rendered	$ 4	146,996			147,000
Restricted shares converted to shares for services rendered,shares	35,000
Stock-based compensation		1,297,798			1,297,798
Net loss			(26,723,607)		(26,723,607)
Foreign currency translation loss				(30,582)	(30,582)
Ending balance, value at Jun. 30, 2021	$ 5,222	265,580,356	(90,911,805)	(10,834)	174,662,939
Ending Balance, Shares at Jun. 30, 2021	52,219,661
Stock issued pursuant to warrants exercised	$ 10	129,990			130,000
Stock issued pursuant to warrants exercised, Shares	100,000
Contingent shares issued pursuant to acquisition agreement	$ 10	797,990			798,000
Contingent Share issued pursuant to Acquisition Agreement, Shares	100,000
Shares issued in lieu of interest on $5 million notes payable extension	$ 5	299,173			299,178
Shares issued in lieu of interest on $5 million notes payable extension,shares	47,115
Shares issued pursuant to LPC purchase agreement	$ 50	4,676,349			4,676,399
Shares issued for fully vested RSUs	1	9,810			9,811
Shares issued pursuant to options exercised		4,913			4,913
Shares issued pursuant to LPC purchase agreement,shares	497,340
Shares issued for fully vested RSUs,shares	6,266
Restricted shares converted to shares for services rendered	$ 4	252,346			252,350
Restricted shares converted to shares for services rendered,shares	35,000
Stock-based compensation		5,238,252			5,238,252
Net loss			(113,433,392)		(113,433,392)
Foreign currency translation loss				(19,602)	(19,602)
Shares issued pursuant to options exercised, shares	1,700
Ending balance, value at Jun. 30, 2022	$ 5,302	$ 276,989,179	$ (204,345,197)	$ (30,436)	$ 72,618,848
Ending Balance, Shares at Jun. 30, 2022	53,007,082

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (113,433,392)	$ (26,723,607)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES :
Depreciation and amortization	123,590	123,534
Change in fair value of contingent consideration	(2,896,627)	3,048,033
Non-cash stock-based compensation expense	5,490,602	1,444,798
Indefinite life intangible assets impairment charge	93,253,000
Amortization of discount on note payable	297,212	296,505
Loss on disposal of fixed assets	18,168
Changes in assets and liabilities:
Other receivables	1,594	342
Prepaid expenses/deposits	461,310	733,739
Accounts payable	1,081,308	(272,318)
Other current liabilities	24,056	30,004
Operating leases, net	(13,516)	(3,440)
Accrued expenses	(139,641)	711,687
NET CASH USED IN OPERATING ACTIVITIES	(15,732,336)	(20,610,723)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5,156)	(48,892)
NET CASH USED IN INVESTING ACTIVITIES	(5,156)	(48,892)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of finance agreement	(560,848)	(546,651)
Proceeds from exercise of warrants	130,000	82,056
Proceeds from exercise of options	4,913
Proceeds from 2021 private placement		5,000,800
Proceeds from direct offering, net of issuance costs		26,843,998
Proceeds from LPC equity agreement	4,676,399	1,221,350
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,250,464	32,601,553
Effect of exchange rates on cash	(5,240)	26,111
NET INCREASE (DECREASE) IN CASH	(11,492,268)	11,968,049
CASH, BEGINNING OF PERIOD	20,664,410	8,696,361
CASH, END OF PERIOD	9,172,142	20,664,410
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest	79,716	89,224
Income Taxes	34	37
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Contingent Shares issued pursuant to Acquisition Agreement	798,000	192,522
Shares issued in lieu of interest expense on note payable	(299,178)	(298,178)
Finance agreement entered into in exchange for prepaid assets	$ 666,875	$ 607,250

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Going Concern 204,345,197 Basis of Presentation Consolidation Reclassification 182,140 Accounting Estimates Subsidiaries 1,250,000 1,350,000 Enochian Biosciences Denmark ApS, a Danish corporation was incorporated on April 1, 2001 (“Enochian Denmark”). On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Enochian Denmark and it became a 100% owned subsidiary of the Registrant subject to 185,053 shares of common stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”). As of June 30, 2022, there are 17,414 COVID-19 Update The COVID-19 pandemic continues to evolve. COVID-19 may cause delays in our research activities. To date, the COVID-19 pandemic has not materially affected our operations. However, it has caused delays in the conduct of experiments due to limitations in resources and supply chain issues, in particular for those third-parties conducting experiments. There have also been increases in the cost to conduct animal studies due to staffing and other limitations. The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us. Functional Currency and Foreign Currency Translation Cash and Cash Equivalents 9,172,142 20,664,410 8,805,495 20,287,212 Property and Equipment Intangible Assets Definite life intangible assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets Indefinite life intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment or whenever events or changes in circumstances indicate the fair value of the license is less than the carrying amount. Goodwill Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 93,253,000 The carrying value of IPR&D and goodwill at June 30, 2022, were $ 61,571,000 11,640,000 Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. Leases Effective June 25, 2022, the Company entered into a sub-lease agreement (see Note 5.) Pursuant to ASC 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease. Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 5.) Research and Development Expenses 8,372,800 15,720,262 Income Taxes Loss Per Share 53,007,082 52,219,661 6,807,820 4,011,653 Fair Value of Financial Instruments Fair Value Measurements ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no assets that use Level 1, 2 or 3 inputs, nor any liabilities that use Level 1 or 2 inputs as of June 30, 2022. Liabilities that use Level 3 inputs held as of June 30, 2022 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian BioPharma (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 21,516,000 1,250,000 The fair value of the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing the contingent consideration liability on the date of acquisition and as of June 30, 2022, include the Company’s stock price on the valuation date of $ 1.93 1.30 0.00 109.0 97 Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and notes payable approximate their recorded values due to their short-term nature. The following table sets forth the liabilities at June 30, 2022 and 2021, which are recorded on the balance sheet at fair value on a recurring basis by level of input within the fair value hierarchy. As required, these are classified based on the lowest level of input that is significant to the fair value measurement: Summary of significant to the fair value measurement Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) Contingent Consideration Liability at June 30, 2022 $ — $ — $ 2,343,318 The roll forward of the contingent consideration liability is as follows: Balance June 30, 2021 — — 6,037,945 Contingent Shares issued pursuant to the Acquisition Agreement (798,000 ) Fair value adjustment — — (2,896,627 ) Balance June 30, 2022 $ — $ — $ 2,343,318 Stock Options and Warrants 5,490,602 1,444,798 Stock-Based Compensation New Accounting Pronouncements Not Yet Adopted

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. We incurred a net loss of approximately $ 113,433,392 26,723,607 9,172,142 204,345,197

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at June 30, 2022 and 2021: Summary of property and equipment Useful Life June 30, 2022 June 30, 2021 Lab equipment and instruments 4 7 $ 546,524 $ 583,421 Leasehold improvements 10 224,629 224,629 Furniture, fixtures, and equipment 4 7 172,861 171,975 Total 944,014 980,025 Less accumulated depreciation (357,478 ) (260,661 ) Net Property and Equipment $ 586,536 $ 719,364 Depreciation expense amounted to $ 108,595 107,647 18,168 18,168

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	NOTE 4 — INTANGIBLE ASSETS AND GOODWILL At June 30, 2022 and 2021, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 44,268 65,906 14,995 15,888 At June 30, 2022 and 2021, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill. At June 30, 2022 and 2021, definite-life and indefinite-life intangible assets consisted of the following: Schedule of life intangible assets Useful Life June 30, 2021 Period Change Effect of Currency Translation June 30, 2022 Definite Life Intangible Assets Patents 20 $ 316,115 $ — (36,858 ) $ 279,257 Less Accumulated Amortization (250,209 ) (14,995 ) 30,215 (234,989 ) Net Definite-Life Intangible Assets $ 65,906 $ (14,995 ) $ (6,643 ) $ 44,268 Indefinite Life Intangible Assets License Agreement $ 154,824,000 $ (93,253,000 ) $ — $ 61,571,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 166,464,000 $ (93,253,000 ) $ — $ 73,211,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Years ended June 30, 2023 $ 11,067 2024 11,067 2025 11,067 2026 11,067 Total $ 44,268 During February 2018, the Company acquired a License Agreement (as licensee) to the HIV therapy being developed as ENOB-HV-01 which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset, it is classified as an indefinite life asset that is tested annually for impairment. Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment indicated that the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value, due to the sublicensing of ENOB HV-01, which required a different valuation approach and the significant decrease in our market capitalization value. Therefore, an impairment adjustment of $ 93,253,000

LEASES

LEASES	12 Months Ended
	Jun. 30, 2022
Leases
LEASES	NOTE 5 — LEASES Operating Leases On November 13, 2017, the Registrant entered into a lease agreement for a term of five years and two months from November 1, 2017 with Plaza Medical Office Building, LLC, pursuant to which the Registrant agreed to lease approximately 2,325 rentable square feet (the “Plaza Lease”). The base rent for the Plaza Lease increased by 3% each year, and ranged from approximately $8,719 per month, for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022. On June 19, 2018, the Registrant entered into a lease agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original lease agreement with an effective date of December 1, 2019, where it expanded the leased area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month as of the date of the amendment to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. Sublease Agreement The Company identified and assessed the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities: Expected lease term 4.95 Incremental borrowing rate 4 Lease and non-lease components Below are the lease commitments for the next 5 years: Lease commitments Years Ending June 30 Lease Expense 2023 $ 298,305 2024 246,004 2025 253,384 2026 260,985 2027 313,836 Thereafter — Less imputed interest (133,178 ) Total $ 1,239,336 Sublease Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022 for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,021.67 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease. The Company will recognize operating income from the sublease on a straight-line basis in its statements of operations over the lease term. During the year ended June 30, 2022 and 2021, the net operating lease expenses were as follows : Schedule of net operating lease expenses Years ended June 30, 2022 2021 Operating Lease Expense $ 356,073 $ 339,094 Sublease income (2,962 ) — Total Net Lease Expense $ 353,111 $ 339,094

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 — NOTES PAYABLE Convertible Notes Payable- 600,000 0.0001 February 6, 2023 6 The holder of the Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price was equal to $ 12.00 1,200,000 24,181 72,875 72,967 February 28, 2024 12 198,439 1.03 29,419 Note Payable- 5,000,000 November 30, 2021 6 188,485 501,370 493,192 On February 11, 2021, the Company entered into an amendment to the Promissory Note in the principal amount of $ 5,000,000 November 30, 2022 6 74,054 298,178 On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date out to November 30, 2023 6 12 47,115 299,178 297,212 296,506 4,577,148 To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral. Finance Agreement 666,875 3.99 56,469 166,625 5,565 Total interest expense recorded for the years ended June 30, 2022 and 2021, was $ 372,844 379,608

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7 — INCOME TAXES The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined. As of June 30, 2022 and 2021, the Company had net operating loss carryforwards of approximately $ 244,899,881 51,327,066 71,299,011 13,536,884 The Company files Danish and U.S. income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2018 for the Danish tax returns and 2017 for the U.S. tax returns. The temporary differences, tax credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2022 and 2021: Summary of deferred tax asset (liabilities) June 30 2022 2021 Excess of tax over book depreciation of fixed assets $ 6,406 $ (6,100 ) Excess of tax over book depreciation of patents 5,716 5,449 Stock/options compensation 2,831,137 1,192,741 Depreciation and amortization 118,020 81,140 Net operating loss carryforwards 71,299,011 13,536,884 Change in tax rate — — Valuation allowance (74,260,290 ) (14,810,114 ) Total Deferred Tax Assets (Liabilities) $ — $ — In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meets the more- likely-than-not condition for recognition, and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets. A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows for the year ended June 30, 2022 and 2021: Summary of reconciliation of income tax expense at federal statutory rate Years ended June 30, 2022 2021 Computed tax at expected statutory rate $ (59,450,176 ) $ (7,070,732 ) Non-US income taxed at different rates — (125,276 ) Non-deductible expenses / other items 34 — Valuation allowance 59,450,176 7,070,732 Income Tax Expense (Benefit) $ 34 $ (125,276 ) The components of income tax expense (benefit) from continuing operations for the years ended June 30, 2022 and 2021 consisted of the following: Summary of components of income tax expense (benefit) from continuing operations Years ended June 30, 2022 2021 Current Income Tax Expense Danish income tax (benefit) $ — $ (125,276 ) Total Current Tax Expense (Benefit) $ — $ (125,276 ) Deferred Income Tax Expense (Benefit) Excess of tax over book depreciation of fixed assets $ 6,406 $ (6,100 ) Excess of tax over book depreciation of patents 5,716 5,449 Stock/options compensation 2,831,137 1,192,741 Depreciation and amortization 118,020 81,140 Net operating loss carryforwards 13,536,884 13,536,884 Change in tax rate — — Change in the valuation allowance (74,260,290 ) (14,810,114 ) Total Deferred Tax Expense $ — $ — Deferred income tax expense (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 — STOCKHOLDERS’ EQUITY Preferred Stock 10,000,000 0.0001 Common Stock 100,000,000 0.0001 53,007,082 52,219,661 Voting — Dividends — Liquidation Rights — Purchase Agreement with Lincoln Park Capital On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 August 1, 2023 In consideration for entering into the Purchase Agreement, we issued 139,567 During the years ended June 30, 2022 and June 30, 2021 we issued 497,340 200,000 4,676,399 1,221,350 14,102,251 Common Stock Issuances On June 17, 2022, the Company issued 47,115 299,178 During the period ending June 30, 2022, the Company issued 497,340 9.25 4,676,399 On April 4, 2022, the Company issued 1,700 2.89 4,913 On January 11, 2022, the Company issued 6,266 40,561 On December 28, 2021, there were 35,000 252,350 On December 24, 2021, the Company issued 100,000 1.30 130,000 7.98 798,000 On June 30, 2021, the Company issued 5,000 On June 16, 2021, the Company issued 3,866,668 7.50 26,843,998 2,156,012 In June 2021, the Company issued 200,000 5.42 1,221,350 From March 18, 2021 through June 9, 2021, the Company issued 1,275,719 3.92 5,000,800 On February 18, 2021, there were 35,000 147,000 On February 11, 2021, the Company issued 74,054 298,178 On December 14, 2020, the Company issued 63,122 1.30 82,056 On December 14, 2020, the Company issued 63,122 3.05 192,522 Acquisition of Enochian Biopharma / Contingently issuable shares On February 16, 2018, the acquisition of Enochian Biopharma was completed. As part of the acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants, which were outstanding at closing. As of June 30, 2022, 1,250,000 Acquisition of Enochian Denmark At June 30, 2022 and 2021, the Company maintained a reserve of 17,414 0 59,835 Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2022, the weighted-average assumptions used to estimate the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are as follows: Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Biosciences Inc. Expected term (in years) 5.0 6.50 Volatility 82.29 90.39 Risk free interest rate 0.77 3.02 Dividend yield 0 The Company recognized stock-based compensation expense related to all equity instruments of $ 5,490,602 1,444,798 6,235,329 Plan Options On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company reserved 1,206,000 On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan. Pursuant to the 2019 Plan, the Company granted options to purchase 3,219,200 31,700 During the year ended June 30, 2022 and 2021, the Company granted options to purchase 65,000 0 During the years ended June 30, 2022 and 2021, the Company granted options to purchase 103,668 184,509 During the years ended June 30, 2022, and 2021, the Company granted options to purchase 60,000 0 During the years ended June 30, 2022, and 2021, the Company granted options to purchase 29,642 0 During the years ended June 30, 2022 and 2021, the Company granted options to purchase 21,979 15,000 All of the above options are exercisable at the market price of the Company’s Common Stock on the date of the grant. To date the Company has granted options under the Plan (“Plan Options”) to purchase 4,828,642 A summary of the Plan Options outstanding at June 30, 2022 is presented below: Summary of stock options outstanding Options Outstanding Options Exercisable Exercise Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 2.00 4.50 264,057 7.62 $ 3.27 233,431 7.41 $ 3.19 $ 4.51 6.50 3,193,369 8.70 $ 4.83 488,372 6.72 $ 6.18 $ 6.51 12.00 850,393 8.27 $ 8.04 543,067 7.56 $ 7.92 Total 4,307,820 8.55 $ 5.37 1,264,869 7.21 $ 6.38 A summary of changes since July 1, 2021 are presented below: Summary of stock option activity Weighted Average Weighted Average Weighted Average Shares Exercise Price Remaining Life Intrinsic Value Outstanding at July 1, 2021 1,329,153 $ 6.24 8.42 $ 511,239 Granted 3,499,489 5.00 Exercised (1,700 ) 2.89 Forfeited (519,122 ) 5.16 Expired/Canceled — Outstanding at June 30, 2022 4,307,820 $ 5.37 8.55 $ — Exercisable at June 30, 2022 1,264,869 $ 6.38 7.21 $ — At June 30, 2022, the Company has 1,264,869 0 Common Stock Purchase Warrants A summary of the warrants outstanding at June 30, 2022, and changes in the warrants in the year ended June 30, 2022 are presented below: Summary of common stock purchase warrants outstanding Weighted Average Weighted Average Underlying Shares Exercise Price Remaining Life Outstanding at July 1, 2021 1,350,000 $ 1.30 1.02 Granted — — — Exercised (100,000 ) 1.30 — Cancelled/Expired — — — Outstanding at June 30, 2022 1,250,000 $ 1.30 0.03 Exercisable at June 30, 2022 1,250,000 $ 1.30 0.03 Summary of common stock purchase warrants Outstanding Equivalent Shares Exercisable Exercise Prices Underlying Shares Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.30 1,250,000 0.03 $ 1.30 1,250,000 $ 1.30 Restricted Stock Units (RSUs) The Company recognized stock-based compensation expense related to RSUs of $ 258,559 147,000 A summary of Restricted Stock Units outstanding at June 30, 2021 and changes in the RSUs in the year ended June 30, 2022 are presented below Summary of restricted stock units outstanding Shares Weighted Average Issuance Weighted Average Remaining Life Weighted Average Intrinsic Outstanding at July 1, 2021 5,000 $ 6.15 .52 $ — Granted 36,266 7.23 — — Exercised (41,266 ) 7.10 — — Cancelled/Expired — — — — Outstanding at June 30, 2022 — $ — — $ —

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 — COMMITMENTS AND CONTINGENCIES Commitments Consulting Agreement G-Tech Agreement 130,000 25,000 275,000 On January 31, 2020, the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, and G-Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections. The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $ 1.2 2 1.2 The cash funding for research costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $ 144,500 1,011,500 2,409,000 1,500,000 The License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 760,000 The License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G Tech on any net sales that may occur under the License Agreement. For the year ended June 30, 2022 and June 30, 2021, the Company paid $ 150,000 10,760,000 On August 25, 2021, the Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the”ALC License Agreement”) with Gümrükcü and SRI and its principals (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free license, with the right to sublicense, his proprietary technology subject to a U.S. patent application, to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $ 600,000 600,000 G-Tech and SRI are controlled by Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company. Shares held for non-consenting stockholders – The 17,414 Service Agreements - The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis. . Contingencies Securities Class Action Litigation Federal Derivative Litigation State Derivative Litigation On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind, G Tech Bio LLC, SG & AW Holdings LLC, and Seraph Research Institute. The Complaint alleges that the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” The defendants have not yet answered the allegations set forth in the Company’s Complaint. On December 28, 2022, the Company received a demand letter on behalf of Weird Science LLC (“Weird Science”), William Anderson Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust alleging that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS. Specifically, the demand letter alleges that the Company “breached its obligations under the Investor Rights Agreement to provide the requisite thirty days’ notice” to Holders of Registrable Securities in connection with SEC Form S-3 filings on July 13, 2020 and February 11, 2022 and demands over $64 million in damages. The Company denies these allegations and intends to vigorously defend against this claim. On March 1, 2021, former Enochian BioSciences Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Enochian BioSciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by Company and Enochian BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 — RELATED PARTY TRANSACTIONS The Company paid G-Tech $ 4,031,500 13,804,000 The Company leased office space from landlord affiliated with G-Tech from May 15, 2022 to August 31, 2022, on a month-to-month basis for a total of $ 43,750 18,750

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 — SUBSEQUENT EVENTS On July 15, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 1,625,000 2.21 2,762,500 Subsequent to June 30, 2022, the Company became involved in a number of legal proceedings. Please see Note 9 above and Item 3 - Legal Proceedings for details of such matters. As of December 30, 2022, the Company entered into amended and restated secured convertible promissory notes (see Note 6.) On December 30, 2022, the Company entered into a security agreement with the Holder (see Note 6.)

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Business	Business
Going Concern	Going Concern 204,345,197
Basis of Presentation	Basis of Presentation
Consolidation	Consolidation
Reclassification	Reclassification 182,140
Accounting Estimates	Accounting Estimates
Subsidiaries	Subsidiaries 1,250,000 1,350,000 Enochian Biosciences Denmark ApS, a Danish corporation was incorporated on April 1, 2001 (“Enochian Denmark”). On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Enochian Denmark and it became a 100% owned subsidiary of the Registrant subject to 185,053 shares of common stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”). As of June 30, 2022, there are 17,414
COVID-19 Update	COVID-19 Update The COVID-19 pandemic continues to evolve. COVID-19 may cause delays in our research activities. To date, the COVID-19 pandemic has not materially affected our operations. However, it has caused delays in the conduct of experiments due to limitations in resources and supply chain issues, in particular for those third-parties conducting experiments. There have also been increases in the cost to conduct animal studies due to staffing and other limitations. The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us.
Functional Currency and Foreign Currency Translation	Functional Currency and Foreign Currency Translation
Cash and Cash Equivalents	Cash and Cash Equivalents 9,172,142 20,664,410 8,805,495 20,287,212
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets Definite life intangible assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets Indefinite life intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment or whenever events or changes in circumstances indicate the fair value of the license is less than the carrying amount.
Goodwill	Goodwill
Impairment of Goodwill and Indefinite Lived Intangible Assets	Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 93,253,000 The carrying value of IPR&D and goodwill at June 30, 2022, were $ 61,571,000 11,640,000
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
Leases	Leases Effective June 25, 2022, the Company entered into a sub-lease agreement (see Note 5.) Pursuant to ASC 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease. Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 5.)
Research and Development Expenses	Research and Development Expenses 8,372,800 15,720,262
Income Taxes	Income Taxes
Loss Per Share	Loss Per Share 53,007,082 52,219,661 6,807,820 4,011,653
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value Measurements ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no assets that use Level 1, 2 or 3 inputs, nor any liabilities that use Level 1 or 2 inputs as of June 30, 2022. Liabilities that use Level 3 inputs held as of June 30, 2022 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian BioPharma (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 21,516,000 1,250,000 The fair value of the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing the contingent consideration liability on the date of acquisition and as of June 30, 2022, include the Company’s stock price on the valuation date of $ 1.93 1.30 0.00 109.0 97 Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, and notes payable approximate their recorded values due to their short-term nature. The following table sets forth the liabilities at June 30, 2022 and 2021, which are recorded on the balance sheet at fair value on a recurring basis by level of input within the fair value hierarchy. As required, these are classified based on the lowest level of input that is significant to the fair value measurement: Summary of significant to the fair value measurement Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) Contingent Consideration Liability at June 30, 2022 $ — $ — $ 2,343,318 The roll forward of the contingent consideration liability is as follows: Balance June 30, 2021 — — 6,037,945 Contingent Shares issued pursuant to the Acquisition Agreement (798,000 ) Fair value adjustment — — (2,896,627 ) Balance June 30, 2022 $ — $ — $ 2,343,318
Stock Options and Warrants	Stock Options and Warrants 5,490,602 1,444,798
Stock-Based Compensation	Stock-Based Compensation
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of significant to the fair value measurement	Summary of significant to the fair value measurement Fair Value Measurements at Reporting Date Using Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) Contingent Consideration Liability at June 30, 2022 $ — $ — $ 2,343,318 The roll forward of the contingent consideration liability is as follows: Balance June 30, 2021 — — 6,037,945 Contingent Shares issued pursuant to the Acquisition Agreement (798,000 ) Fair value adjustment — — (2,896,627 ) Balance June 30, 2022 $ — $ — $ 2,343,318

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of property and equipment	Summary of property and equipment Useful Life June 30, 2022 June 30, 2021 Lab equipment and instruments 4 7 $ 546,524 $ 583,421 Leasehold improvements 10 224,629 224,629 Furniture, fixtures, and equipment 4 7 172,861 171,975 Total 944,014 980,025 Less accumulated depreciation (357,478 ) (260,661 ) Net Property and Equipment $ 586,536 $ 719,364

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of life intangible assets	Schedule of life intangible assets Useful Life June 30, 2021 Period Change Effect of Currency Translation June 30, 2022 Definite Life Intangible Assets Patents 20 $ 316,115 $ — (36,858 ) $ 279,257 Less Accumulated Amortization (250,209 ) (14,995 ) 30,215 (234,989 ) Net Definite-Life Intangible Assets $ 65,906 $ (14,995 ) $ (6,643 ) $ 44,268 Indefinite Life Intangible Assets License Agreement $ 154,824,000 $ (93,253,000 ) $ — $ 61,571,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 166,464,000 $ (93,253,000 ) $ — $ 73,211,000
Schedule of expected future amortization expense	Schedule of expected future amortization expense Years ended June 30, 2023 $ 11,067 2024 11,067 2025 11,067 2026 11,067 Total $ 44,268

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2022
Leases
Lease commitments	Lease commitments Years Ending June 30 Lease Expense 2023 $ 298,305 2024 246,004 2025 253,384 2026 260,985 2027 313,836 Thereafter — Less imputed interest (133,178 ) Total $ 1,239,336
Schedule of net operating lease expenses	Schedule of net operating lease expenses Years ended June 30, 2022 2021 Operating Lease Expense $ 356,073 $ 339,094 Sublease income (2,962 ) — Total Net Lease Expense $ 353,111 $ 339,094

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Summary of deferred tax asset (liabilities)	Summary of deferred tax asset (liabilities) June 30 2022 2021 Excess of tax over book depreciation of fixed assets $ 6,406 $ (6,100 ) Excess of tax over book depreciation of patents 5,716 5,449 Stock/options compensation 2,831,137 1,192,741 Depreciation and amortization 118,020 81,140 Net operating loss carryforwards 71,299,011 13,536,884 Change in tax rate — — Valuation allowance (74,260,290 ) (14,810,114 ) Total Deferred Tax Assets (Liabilities) $ — $ —
Summary of reconciliation of income tax expense at federal statutory rate	Summary of reconciliation of income tax expense at federal statutory rate Years ended June 30, 2022 2021 Computed tax at expected statutory rate $ (59,450,176 ) $ (7,070,732 ) Non-US income taxed at different rates — (125,276 ) Non-deductible expenses / other items 34 — Valuation allowance 59,450,176 7,070,732 Income Tax Expense (Benefit) $ 34 $ (125,276 )
Summary of components of income tax expense (benefit) from continuing operations	Summary of components of income tax expense (benefit) from continuing operations Years ended June 30, 2022 2021 Current Income Tax Expense Danish income tax (benefit) $ — $ (125,276 ) Total Current Tax Expense (Benefit) $ — $ (125,276 ) Deferred Income Tax Expense (Benefit) Excess of tax over book depreciation of fixed assets $ 6,406 $ (6,100 ) Excess of tax over book depreciation of patents 5,716 5,449 Stock/options compensation 2,831,137 1,192,741 Depreciation and amortization 118,020 81,140 Net operating loss carryforwards 13,536,884 13,536,884 Change in tax rate — — Change in the valuation allowance (74,260,290 ) (14,810,114 ) Total Deferred Tax Expense $ — $ —

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Summary of weighted-average assumptions used to estimate the fair values of the stock options granted	Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Biosciences Inc. Expected term (in years) 5.0 6.50 Volatility 82.29 90.39 Risk free interest rate 0.77 3.02 Dividend yield 0
Summary of stock options outstanding	Summary of stock options outstanding Options Outstanding Options Exercisable Exercise Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 2.00 4.50 264,057 7.62 $ 3.27 233,431 7.41 $ 3.19 $ 4.51 6.50 3,193,369 8.70 $ 4.83 488,372 6.72 $ 6.18 $ 6.51 12.00 850,393 8.27 $ 8.04 543,067 7.56 $ 7.92 Total 4,307,820 8.55 $ 5.37 1,264,869 7.21 $ 6.38
Summary of stock option activity	Summary of stock option activity Weighted Average Weighted Average Weighted Average Shares Exercise Price Remaining Life Intrinsic Value Outstanding at July 1, 2021 1,329,153 $ 6.24 8.42 $ 511,239 Granted 3,499,489 5.00 Exercised (1,700 ) 2.89 Forfeited (519,122 ) 5.16 Expired/Canceled — Outstanding at June 30, 2022 4,307,820 $ 5.37 8.55 $ — Exercisable at June 30, 2022 1,264,869 $ 6.38 7.21 $ —
Summary of common stock purchase warrants outstanding	Summary of common stock purchase warrants outstanding Weighted Average Weighted Average Underlying Shares Exercise Price Remaining Life Outstanding at July 1, 2021 1,350,000 $ 1.30 1.02 Granted — — — Exercised (100,000 ) 1.30 — Cancelled/Expired — — — Outstanding at June 30, 2022 1,250,000 $ 1.30 0.03 Exercisable at June 30, 2022 1,250,000 $ 1.30 0.03
Summary of common stock purchase warrants	Summary of common stock purchase warrants Outstanding Equivalent Shares Exercisable Exercise Prices Underlying Shares Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.30 1,250,000 0.03 $ 1.30 1,250,000 $ 1.30
Summary of restricted stock units outstanding	Summary of restricted stock units outstanding Shares Weighted Average Issuance Weighted Average Remaining Life Weighted Average Intrinsic Outstanding at July 1, 2021 5,000 $ 6.15 .52 $ — Granted 36,266 7.23 — — Exercised (41,266 ) 7.10 — — Cancelled/Expired — — — — Outstanding at June 30, 2022 — $ — — $ —

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Stock-based compensation	$ 5,238,252	$ 1,297,798
Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock-based compensation	5,490,602	1,444,798
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Contingent Consideration Liability
Balance at beginning
Fair value adjustment
Balance at end
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Contingent Consideration Liability
Balance at beginning
Fair value adjustment
Balance at end
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Contingent Consideration Liability	2,343,318
Balance at beginning	6,037,945
Contingent Shares issued pursuant to the Acquisition Agreement	(798,000)
Fair value adjustment	(2,896,627)
Balance at end	$ 2,343,318	$ 6,037,945

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Accumulated deficit	$ 204,345,197	$ 90,911,805
General and administrative expenses		182,140
Escrow Shares remaining	17,414
Cash	$ 9,172,142	20,664,410	$ 8,696,361
Cash held in financial institutions	8,805,495	20,287,212
Goodwill impairment loss	93,253,000
IPR&D	61,571,000	154,824,000
Goodwill	11,640,000	11,640,000
Research and development expense	$ 8,372,800	$ 15,720,262
Common Stock outstanding	53,007,082	52,219,661
Potential dilutive shares	6,807,820	4,011,653
Common stock shares issued	18,081,962
Fair value	$ 21,516,000
Contingent shares issuable	1,250,000
Stock price per share	$ 1.93
Warrants exercise price	$ 1.30
Risk-free rate	0%
Expected volatility rate	109%
Digital call rate	97%
Enochian Biopharma Inc. [Member]
Common shares contingently issuable	1,250,000	1,350,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 113,433,392	$ 26,723,607
Cash and cash equivalents	9,172,142	20,664,410	$ 8,696,361
Accumulated deficit	$ 204,345,197	$ 90,911,805

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Total	$ 944,014	$ 980,025
Less Accumulated Depreciation	(357,478)	(260,661)
Net Property and Equipment	586,536	719,364
Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Total	$ 546,524	583,421
Lab Equipment And Instruments [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Lab Equipment And Instruments [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	224,629
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 172,861	$ 171,975
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 108,595	$ 107,647
Disposed of property and equipment	18,168
Loss on disposal of property and equipment	$ 18,168

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Definite-life intangible assets	$ 44,268	$ 65,906
Period Change	(14,995)
Effect of Currency Translation	(6,643)
Indefinite Life Intangible Assets	73,211,000	166,464,000
Period Changes	$ (93,253,000)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years
Definite-life intangible assets	$ 279,257	316,115
Period Change	0
Effect of Currency Translation	(36,858)
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change	(14,995)
Effect of Currency Translation	30,215
Accumulated Amortization	234,989	(250,209)
Accumulated Amortization	(234,989)	250,209
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	61,571,000	154,824,000
Period Changes	(93,253,000)
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	$ 11,640,000	$ 11,640,000

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL (Details 1) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 11,067
2024	11,067
2025	11,067
2026	11,067
Total	$ 44,268	$ 65,906

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Definite-life intangible assets	$ 44,268	$ 65,906
Amortization expense	14,995	$ 15,888
Impairment adjustment of intangible assets	$ 93,253,000

LEASES (Details)

LEASES (Details)	Jun. 30, 2022 USD ($)
Leases
2023	$ 298,305
2024	246,004
2025	253,384
2026	260,985
2027	313,836
Thereafter
Less imputed interest	(133,178)
Total	$ 1,239,336

LEASES (Details 1)

LEASES (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases
Operating Lease Expense	$ 356,073	$ 339,094
Sublease income	(2,962)
Total Net Lease Expense	$ 353,111	$ 339,094

LEASES (Details Narrative)

LEASES (Details Narrative)		1 Months Ended
	Nov. 13, 2018	Jun. 20, 2022	Jun. 19, 2019	Jun. 30, 2022
Leases
Lease premises, description	On November 13, 2017, the Registrant entered into a lease agreement for a term of five years and two months from November 1, 2017 with Plaza Medical Office Building, LLC, pursuant to which the Registrant agreed to lease approximately 2,325 rentable square feet (the “Plaza Lease”). The base rent for the Plaza Lease increased by 3% each year, and ranged from approximately $8,719 per month, for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022.		On June 19, 2018, the Registrant entered into a lease agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original lease agreement with an effective date of December 1, 2019, where it expanded the leased area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month as of the date of the amendment to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
Weighted-average remaining term				4 years 11 months 12 days
Weighted-average discount rate				4%
Sublease agreement description		On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022 for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,021.67 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Jan. 11, 2022

Jul. 08, 2021

Feb. 11, 2021

Dec. 30, 2022

Mar. 17, 2022

Nov. 30, 2021

Mar. 31, 2020

Mar. 30, 2020

Jun. 30, 2022

Jun. 30, 2021

Dec. 20, 2022

Dec. 24, 2021

Dec. 23, 2021

Jun. 16, 2021

Feb. 18, 2021

Dec. 14, 2020

Debt Instrument [Line Items]

Stock price

$ 1.30

$ 7.98

$ 7.50

Maturity date

Aug. 01, 2023

Nov. 30, 2022

Convertible Notes Payable, Noncurrent

$ 1,200,000

Accrued interest

24,181

Interest Expense, Other

$ 72,875

$ 72,967

Number of shares issued

6,266

47,115

Issuance of common stock

$ 299,178

Unsecured note principal amount

$ 5,000,000

$ 666,875

Interest at the fixed rate

6%

3.99%

Shares issued

74,054

47,115

74,054

5,000

3,866,668

35,000

63,122

Market price

$ 298,178

Monthly installments

$ 56,469

Other current liabilities

166,625

Interest expense related to agreement

5,565

interest expense

372,844

$ 379,608

Convertible Notes Payables [Member]

Debt Instrument [Line Items]

Principal amount

$ 600,000

Stock price

$ 0.0001

$ 1.03

Maturity date

Feb. 06, 2023

Interest rate

6%

Debt Instrument, Convertible, Conversion Price

$ 12

Secured Notes [Member]

Debt Instrument [Line Items]

Maturity date

Feb. 28, 2024

Interest rate

12%

Number of shares issued

198,439

Number of shares issued

29,419

Note Payable [Member]

Debt Instrument [Line Items]

Principal amount

$ 5,000,000

Maturity date

Nov. 30, 2021

Interest rate

6%

Stock issued for debt conversion, shares

188,485

Stock issued for debt conversion

$ 501,370

Issuance of common stock

$ 493,192

Promissory Note [Member]

Debt Instrument [Line Items]

Maturity date

Nov. 30, 2023

Discount amortization

$ 297,212

$ 296,506

Debt net of discount

$ 4,577,148

Promissory Note [Member] | Minimum [Member]

Debt Instrument [Line Items]

Interest at the fixed rate

6%

Promissory Note [Member] | Maximum [Member]

Debt Instrument [Line Items]

Interest at the fixed rate

12%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Excess of tax over book depreciation of fixed assets	$ 6,406	$ (6,100)
Excess of tax over book depreciation of patents	5,716	5,449
Stock/options compensation	2,831,137	1,192,741
Depreciation and amortization	118,020	81,140
Net operating loss carryforwards	71,299,011	13,536,884
Change in tax rate
Valuation allowance	(74,260,290)	(14,810,114)
Total Deferred Tax Assets (Liabilities)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Computed tax at expected statutory rate	$ (59,450,176)	$ (7,070,732)
Non-US income taxed at different rates		(125,276)
Non-deductible expenses / other items	34
Valuation allowance	59,450,176	7,070,732
Income Tax Expense (Benefit)	$ 34	$ (125,276)

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Current Income Tax Expense
Danish income tax (benefit)		$ (125,276)
Total Current Tax Expense (Benefit)		(125,276)
Deferred Income Tax Expense (Benefit)
Excess of tax over book depreciation of fixed assets	6,406	(6,100)
Excess of tax over book depreciation of patents	5,716	5,449
Stock/options compensation	2,831,137	1,192,741
Depreciation and amortization	118,020	81,140
Net operating loss carryforwards	13,536,884	13,536,884
Change in tax rate
Change in the valuation allowance	(74,260,290)	(14,810,114)
Total Deferred Tax Expense

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - United States Tax [Member] - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 244,899,881	$ 51,327,066
Deferred tax assets	$ 71,299,011	$ 13,536,884

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)	12 Months Ended
	Jun. 30, 2022
Volatility	109%
Risk free interest rate	0%
Enochian Biosciences [Member]
Dividend yield	0%
Enochian Biosciences [Member] | Minimum [Member]
Expected term (in years)	5 years
Volatility	82.29%
Risk free interest rate	0.77%
Enochian Biosciences [Member] | Maximum [Member]
Expected term (in years)	6 years 6 months
Volatility	90.39%
Risk free interest rate	3.02%

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	4,307,820	1,329,153
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 6 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 5.37	$ 6.24
Options Exercisable	1,264,869
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 2 months 15 days
Options Exercisable, Weighted Average Exercise Price	$ 6.38
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	264,057
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 7 months 13 days
Options Outstanding, Weighted Average Exercise Price	$ 3.27
Options Exercisable	233,431
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 4 months 28 days
Options Exercisable, Weighted Average Exercise Price	$ 3.19
Exercise Price Range 1 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	2
Exercise Price Range 1 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 4.50
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	3,193,369
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 4.83
Options Exercisable	488,372
Options Exercisable, Weighted Average Remaining Contractual Life (years)	6 years 8 months 19 days
Options Exercisable, Weighted Average Exercise Price	$ 6.18
Exercise Price Range 2 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.51
Exercise Price Range 2 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 6.50
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	850,393
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 3 months 7 days
Options Outstanding, Weighted Average Exercise Price	$ 8.04
Options Exercisable	543,067
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 6 months 21 days
Options Exercisable, Weighted Average Exercise Price	$ 7.92
Exercise Price Range 3 [Member] | Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.51
Exercise Price Range 3 [Member] | Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 12

STOCKHOLDERS' EQUITY (Details 2

STOCKHOLDERS' EQUITY (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Option [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period	1,329,153
Weighted Average Exercise Price, Outstanding at beginning of period	$ 6.24
Weighted Average remaining life, Outstanding at beginning of period		8 years 5 months 1 day
Weighted Average Intrinsic Value, Outstanding at end of period		$ 511,239
Granted	3,499,489
Weighted average exercise price, Granted	$ 5
Exercised	(1,700)
Weighted average exercise price, Exercised	$ 2.89
Options Outstanding, Forfeited	(519,122)
Weighted Average Exercise Price, Forfeited	$ 5.16
Cancelled/Expired
Options Outstanding at end of period	4,307,820	1,329,153
Weighted Average Exercise Price, Outstanding at end of period	$ 5.37	$ 6.24
Weighted Average remaining life, Outstanding	8 years 6 months 18 days
Exercisable end of period	1,264,869
Weighted average exercise price, Exercisable end of period	$ 6.38
Weighted Average Remaining Life, Exercisable end of period	7 years 2 months 15 days
Weighted Average Intrinsic Value, Exercisable end of period
Common Stock Purchase Warrants [Member]
Option Indexed to Issuer's Equity [Line Items]
Granted
Weighted average exercise price, Granted
Exercised	(100,000)
Weighted average exercise price, Exercised	$ 1.30
Cancelled/Expired
Weighted Average remaining life, Outstanding	10 days	1 year 7 days
Exercisable end of period	1,250,000
Weighted average exercise price, Exercisable end of period	$ 1.30
Outstanding at beginning of period	1,350,000
Weighted average exercise price, Outstanding at beginning of period	$ 1.30
Weighted average exercise price, Expired
Outstanding at end of period	1,250,000	1,350,000
Weighted average exercise price, Outstanding at end of period	$ 1.30	$ 1.30
Weighted Average remaining life, Exercisable end of period	10 days

STOCKHOLDERS' EQUITY (Details 3

STOCKHOLDERS' EQUITY (Details 3) - Warrant [Member] - Exercise Price Range 4 [Member]	12 Months Ended
	Jun. 30, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Prices	$ 1.30
Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares | shares	1,250,000
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)	10 days
Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price	$ 1.30
Equivalent Shares Exercisable, Number Exercisable | shares	1,250,000
Equivalent Shares Exercisable, Weighted Average Exercise Price	$ 1.30

STOCKHOLDERS' EQUITY (Details 4

STOCKHOLDERS' EQUITY (Details 4) - Restricted Stock Units (RSUs) [Member] - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding at beginning of period	5,000
Weighted average exercise price, Outstanding at beginning of period	$ 6.15
Weighted Average remaining life, Outstanding		6 months 7 days
Weighted Average Intrinsic Value, Outstanding at end of period
Granted	36,266
Weighted average exercise price, Granted	$ 7.23
Weighted Average Intrinsic Value, granted
Exercised	(41,266)
Weighted average exercise price, Exercised	$ 7.10
Weighted Average Intrinsic Value, exercised
Cancelled/Expired
Weighted average exercise price, Expired
Weighted Average Intrinsic Value, cancelled/ expired
Outstanding at end of period		5,000
Weighted average exercise price, Outstanding at end of period		$ 6.15

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)						1 Months Ended							3 Months Ended	12 Months Ended
	Apr. 04, 2022	Jan. 11, 2022	Dec. 14, 2021	Jul. 08, 2021	Feb. 11, 2021	Mar. 17, 2022	Dec. 28, 2021	Dec. 24, 2021	Jun. 30, 2021	Jun. 16, 2021	Feb. 18, 2021	Jun. 16, 2020	Jun. 09, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 23, 2021	Dec. 14, 2020	Jul. 21, 2020	Jul. 08, 2020	Feb. 06, 2014
Subsidiary, Sale of Stock [Line Items]
Preferred Stock, Shares Authorized									10,000,000					10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share									$ 0.0001					$ 0.0001	$ 0.0001
Common stock, shares authorized									100,000,000					100,000,000	100,000,000
Common stock, par value									$ 0.0001					$ 0.0001	$ 0.0001
Common stock, shares issued									52,219,661					53,007,082	52,219,661
Common stock, shares outstanding									52,219,661					53,007,082	52,219,661
Obligation to purchase																			$ 20,000,000
Maturity date				Aug. 01, 2023	Nov. 30, 2022
Issued shares					74,054	47,115			5,000	3,866,668	35,000			74,054	5,000		63,122
Number of shares issued		6,266				47,115
Number of shares issued, value						$ 299,178
Common stock at price								$ 1.30		$ 7.50						$ 7.98
[custom:NoncashTransactionImpactedStockholdersEquity-0]								$ 798,000
Net proceeds			$ 82,056							$ 26,843,998	$ 147,000
Issuance costs												$ 2,156,012
Common stock valued					$ 298,178				$ 5,222					$ 5,302	$ 5,222
Strike price																	$ 1.30
Common stock value price																	$ 3.05
Non cash transaction Impacted on stockholders equity																	$ 192,522
Common stock reserved for issuance														17,414
Stock based compensation expense														$ 5,490,602	1,444,798
Unrecognized compensation cost														6,235,329
Stock based compensation														$ 5,238,252	1,297,798
Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Options Exercisable														1,264,869
Employee Stock Option One [Member]
Subsidiary, Sale of Stock [Line Items]
Intrinsic value of stock option														$ 0
2014 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance																				1,206,000
Plan Options [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														4,828,642
Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	1,700
Number of shares issued, value	$ 4,913	$ 40,561
Common stock at price	$ 2.89
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued								100,000
Number of shares issued for services							35,000
Number of shares issued for services, value							$ 252,350
Proceeds from warrant								$ 130,000
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation														$ 258,559	$ 147,000
Agreement And Plan Of Merger Agreement Axis [Member] | E B I And Weird Science L L C [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares contingently issuable														1,250,000
Lincoln Park [Member] | Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued														497,340	200,000
Number of shares issued, value														$ 4,676,399	$ 1,221,350
Remaining value available under purchase agreement														$ 14,102,251
Common stock at price														$ 9.25
DanDrit Denmark [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued														0	59,835
Employees [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														65,000	0
Employees [Member] | N 2019 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														3,219,200	31,700
Board Of Directors And Scientific Advisory Board [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														103,668	184,509
Consulting Services [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														60,000	0
Consulting Services 1 [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														29,642	0
Consulting Services 2 [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted														21,979	15,000
Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issued shares																		139,567
Lincoln Park [Member]
Subsidiary, Sale of Stock [Line Items]
Issued shares									200,000						200,000
Common stock at price									$ 5.42						$ 5.42
Net proceeds									$ 1,221,350
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Issued shares													1,275,719
Common stock at price													$ 3.92
Net proceeds													$ 5,000,800

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended			12 Months Ended
	Oct. 10, 2021	Feb. 06, 2021	Jul. 09, 2019	Aug. 25, 2021	Jan. 31, 2021	Jan. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Nov. 15, 2019
Net Investment Income [Line Items]
Research and development expenses							$ 8,372,800	$ 15,720,262
Up-front payment									$ 10,000,000
Payment for expenditures									$ 760,000
Prevention and Treatment research							$ 150,000	10,760,000
Initial payment				$ 600,000
Paid initial payment	$ 600,000
Common stock reserved for issuance							17,414
Compensation description							The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis.
G Tech [Member] | License Agreement [Member]
Net Investment Income [Line Items]
Payment for license		$ 1,200,000				$ 1,200,000
Royalty Percentage					$ 0.02
Milestone payments		$ 1,500,000
Consulting Agreement [Member] | G Tech [Member]
Net Investment Income [Line Items]
Consulting expenses			$ 130,000
Monthly consulting fee							$ 25,000
Research and development expenses							275,000	275,000
Monthly research costs							144,500
Payment for scientific staffing resources							$ 1,011,500	$ 2,409,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	4 Months Ended	12 Months Ended
	Aug. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Related party costs		$ 4,031,500	$ 13,804,000
G Tech [Member]
Related Party Transaction [Line Items]
Lease expenses	$ 43,750
Lease expenses current	$ 18,750

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended
	Jul. 15, 2022	Mar. 17, 2022	Dec. 24, 2021	Dec. 23, 2021	Jun. 16, 2021
Proceeds from issuance of common stock		$ 299,178
Share price			$ 1.30	$ 7.98	$ 7.50
Warrant [Member]
Number of shares purchased	1,250,000
Proceeds from issuance of common stock	$ 1,625,000
Share price	$ 2.21
Noncash or Part Noncash Acquisition, Accounts Receivable Acquired	$ 2,762,500